TANAKA Junji
   Department   Other, Other
   Position  
Article types Original article
Language English
Peer review Peer reviewed
Title A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without posttransplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemia-lymphoma.
Journal Formal name：Bone marrow transplantation
Abbreviation：Bone Marrow Transplant
ISSN code：(1476-5365)0268-3369(Linking)
Domestic / ForeginForegin
Volume, Issue, Page 54(8),pp.1266-1274
Author and coauthor Yoshimitsu Makoto†, Utsunomiya Atae, Fuji Shigeo, Fujiwara Hiroshi, Fukuda Takahiro, Ogawa Hiroyasu, Takatsuka Yoshifusa, Ishitsuka Kenji, Yokota Akira, Okumura Hirokazu, Ishii Kazuyoshi, Nishikawa Akinori, Eto Tetsuya, Yonezawa Akihito, Miyashita Kaname, Tsukada Junichi, Tanaka Junji, Atsuta Yoshiko, Kato Koji,
Publication date 2019/08
Summary Currently, allogeneic hematopoietic stem cell transplantation (allo-HCT) is the only available curative modality for patients with adult T-cell leukemia-lymphoma (ATL). When used in conjunction with posttransplantation cyclophosphamide (PTCY) for graft-versus-host disease prophylaxis, allo-HCT from an HLA haplo-identical donor yields promising outcomes for many diseases other than ATL. However, appropriate comparisons with other donor sources, especially cord blood and conventional HLA haplo-identical donors, are needed to validate the safety and efficacy of this modality. In this study, we retrospectively evaluated the outcome of allo-HCT without PTCY in patients with ATL registered in the Japan Society for Hematopoietic Cell Transplantation TRUMP database between 1985 and 2015. During that period, 46 patients received allo-HCT without PTCY and survivors were followed for a median of 2316.5 days (range: 220-3884 days). Although the estimated 1- and 5-year overall survival rates of the entire cohort were 34.5% and 17.7%, respectively, the cumulative 1- and 5-year non-ATL mortality rates of 41.3% and 55.8%, respectively, were high. The results of our study will serve as a platform for discussions of the safety and efficacy of haplo-HCT for future clinical trials in patients with ATL.
DOI 10.1038/s41409-018-0400-5
PMID 30546068